New rheumatoid arthritis drug candidate passes first safety check in healthy volunteers

NCT ID NCT06883695

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety of a new drug called SHR-3045 in 40 healthy adults. The study was randomized, double-blind, and placebo-controlled, meaning some participants got the drug and some got a dummy shot. The main goal was to see if the drug causes any side effects and how the body processes it. This is a first step toward possibly treating rheumatoid arthritis, but much more research is needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SHR-3045
What this could lead to
If this drug proves safe and effective in future trials, it could become a new treatment option for rheumatoid arthritis.
What could go wrong
This is a very early phase 1 study in only 40 healthy people, not patients. It only looks at safety and how the drug moves through the body, not whether it works for arthritis. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, 200080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.